Table 6 Adverse effects
| Â | NAC group A (N=80) | High-risk control group B (N=40) | ||||||
|---|---|---|---|---|---|---|---|---|
Grades 1–2 | Grade 3 | Grade 4 | Grade 5 | Grades 1–2 | Grade 3 | Grade 4 | Grade 5 | |
Skina | 25(31) | 0 | 0 | 0 | 8(20) | 0 | 0 | 0 |
Gastrointestinala | 54(67) | 16(20) | 0 | 0 | 30(70) | 7(18) | 0 | 0 |
Hepatobiliary/pancreatica | 14(17) | 5(6) | 0 | 0 | 5(13) | 1(3) | 0 | 0 |
Cardiac | 12(15) | 1(1) | 0 | 0 | 7(18) | 0 | 0 | 0 |
Renal/genitourinary | 8(10) | 0 | 0 | 0 | 6(15) | 0 | 0 | 0 |
Infectionsb | 5(6) | 16(20) | 0 | 3(4) | 2(5) | 8(20) | 1(3) | 1(3) |
Nervous system disorders | 2(3) | 0 | 0 | 0 | 1(3) | 0 | 0 | 0 |